2012 Drug Carriers in Medicine and Biology Gordon Research Conference

2012年医学和生物学药物载体戈登研究会议

• 批准号: 8396077
• 负责人: Vladimir R Muzykantov
• 金额: $ 1.2万
• 依托单位: GORDON RESEARCH CONFERENCES
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-07-20 至 2013-07-19
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8396077
• 关键词: Age; Applied Research; Area; Attention; Basic Science; Behavior; Biocompatible Materials; Biological; Biological Response Modifier Therapy; Biology; Biomedical Engineering; Biotechnology; Blood Vessels; Cardiovascular Diseases; Cellular biology; Clinical; Clinical Trials; Communicable Diseases; Consultations; Data; Development; Diagnosis; Diagnostic; Disease; Drug Carriers; Drug Delivery Systems; Environment; Extramural Activities; Female; Financial Support; Funding; Gender; Goals; Health; Human; Image; In Vitro; Industry; Intervention; Knowledge; Location; Lung diseases; Malignant Neoplasms; Medical; Medicine; Mission; Modeling; Molecular; Molecular Biology; Molecular Target; Nanotechnology; Nature; Organism; Participant; Pathology; Pharmaceutical Preparations; Pharmacologic Substance; Pharmacotherapy; Prophylactic treatment; Research; Research Personnel; Research Priority; Research Training; Science; Scientist; Seasons; Site; Small Interfering RNA; Specific qualifier value; Staging; Testing; Therapeutic; Time; Training; Translating; Translations; Work; body system; career; clinical application; clinical practice; design; enzyme therapy; imaging probe; improved; in vivo; insight; interdisciplinary approach; medical specialties; meetings; member; molecular imaging; multidisciplinary; nervous system disorder; novel; planetary Atmosphere; posters; professor; programs; symposium; targeted delivery; therapeutic target; trafficking; vaccin protein; working group

DESCRIPTION (provided by applicant): We seek partial support for the Gordon Research Conference on Drug Carriers in Medicine and Biology, to be held at Waterville Valley, NH, August 12-17 in 2012. The conference will focus on topics that represent key research areas in carriers for drug and imaging probe delivery and targeting including design of novel carriers and materials, vascular drug delivery, targeting cancer, intracellular delivery and trafficking, vaccin delivery, local delivery and barriers, drug delivery to organ systems, biological control of the delivery and its effects and translational aspects of drug carriers. The sub-theme of the conference will thus be "Translational drug carriers: from design and understanding mechanism of action to clinical use". Speakers and discussion leaders are recognized leaders in their fields and were chosen in consultation with scientists who represent the breadth of the field of drug delivery. Special attention has been given to diversity of the speakers and other participants. The tentative program reflects this in terms of gender, age, career stage, location and other diversity parameters. In particular, we projected at least one short-talk in each session given by promising investigators at early career stage (up to early Associate Professors and young industrial researchers). We have devised an extremely high-quality program that features about 50% female speakers. We will boost diversity further through registration and via financial support for the attendance of members of under- represented groups (especially trainees). This proposal seeks partial extramural funding specifically for this goal. Training aspects are incorporated into the program in the form of three poster sessions and short talks selected from the poster presentations given by trainees. Traditional informal, collegial atmosphere of this GRC, in which about a hundred participants interact across their specialties, ages, affiliations and career stages facilitates both research and training mission of this meeting. The specific objectives of the GRC are: 1) To provide a forum for discussion of the latest drug carrier research. 2) To bring together scientists working in the drug delivery design (i.e., bioengineering, biotechnology, imaging and pharmaceutical sciences), those focused in the biomedical aspects of the field (i.e., cell and molecular biology, immunological and medical aspects) and representatives of industry, to integrate across all translational. 3) To identify priority research themes for the coming years by identifying gaps in knowledge and improving conceptual models. 4) To continue to provide a high quality and accessible arena for interaction between trainees and senior researchers. PUBLIC HEALTH RELEVANCE: Targeted delivery of drugs and imaging agents to the sites of pathology where their activity is needed is a Holy Grail of modern biomedicine. It will provide safer and more effective means for diagnosis, prophylaxis and treatment of prevalent disease conditions including cancer, infectious diseases, cardiovascular, pulmonary and neurological disorders, among a plethora of human maladies. Translation of these drug carriers into the biomedical domain, industrial development and clinical use will benefit a plethora of diagnostic and pharmacotherapy approaches, especially those employing novel classes of molecular imaging probes and biologicals including siRNA, enzyme therapies and biological modulators. These new means for targeted molecular interventions and imaging hold promise to provide a major impact on human health and, in fact, revolutionize modern biomedicine.

描述（由申请人提供）：我们寻求部分支持戈登研究会议药物载体在医学和生物学，将在沃特维尔谷，NH，8月12日至17日在2012年。会议将集中讨论代表药物和成像探针递送和靶向载体的关键研究领域的主题，包括新型载体和材料的设计，血管药物递送，靶向癌症，细胞内递送和贩运，疫苗递送，局部递送和屏障，药物递送到器官系统，药物载体的生物控制及其影响和翻译方面。因此，会议的分主题将是“转化药物载体：从设计和理解作用机制到临床应用”。演讲者和讨论领导者是各自领域公认的领导者，并与代表药物输送领域广度的科学家协商选择。特别注意发言者和其他与会者的多样性。暂定方案在性别、年龄、职业阶段、地点和其他多样性参数方面反映了这一点。特别是，我们预计在每个会议上至少有一个简短的谈话，由有前途的研究人员在职业生涯的早期阶段（早期副教授和年轻的工业研究人员）。我们设计了一个非常高质量的节目，其中女性发言者约占50%。我们将通过注册和通过对代表性不足的团体成员（特别是受训人员）的出席提供财政支持，进一步促进多样性。该提案寻求专门为此目的提供部分校外资金。培训内容以三个海报会议和从学员提供的海报演示中选择的简短演讲的形式纳入该计划。传统的非正式的，学院的气氛中，约有一百名参与者在他们的专业，年龄，隶属关系和职业阶段的互动，促进了本次会议的研究和培训使命。该研讨会的具体目标是：1）提供一个讨论最新药物载体研究的论坛。2)为了将从事药物递送设计的科学家聚集在一起（即，生物工程、生物技术、成像和制药科学），那些专注于该领域的生物医学方面的科学（即，细胞和分子生物学，免疫学和医学方面）和行业代表，以整合所有翻译。3)通过确定知识差距和改进概念模型，确定未来几年的优先研究主题。4)继续为学员和高级研究人员提供一个高质量和方便的竞技场。 公共卫生相关性：将药物和显像剂靶向递送到需要其活性的病理部位是现代生物医学的圣杯。它将为诊断、预防和治疗流行疾病提供更安全和更有效的手段，这些疾病包括癌症、传染病、心血管、肺部和神经系统疾病以及多种人类疾病。将这些药物载体转化为生物医学领域、工业开发和临床应用将有利于大量的诊断和药物治疗方法，特别是那些采用新型分子成像探针和生物制剂（包括siRNA、酶疗法和生物调节剂）的方法。这些针对性分子干预和成像的新手段有望对人类健康产生重大影响，事实上，这将彻底改变现代生物医学。